Browsing by Author "Eskiyurt, N"

Now showing 1 - 9 of 9
  • No Thumbnail Available
    Item
    Assessment of the Relationship Between Vitamin D Level and Non-specific Musculoskeletal System Pain: A Multicenter Retrospective Study (Stroke Study Group)
    Karahan, AY; Hüner, B; Kuran, B; Sezer, N; Çelik, C; Salbas, E; Ordahan, B; Karaca, G; Yilmaz, H; Gündüz, B; Erhan, B; Bugdayci, DS; Bardak, A; Paker, N; Külcü, DG; Yaliman, A; Atalay, NS; Yildiz, N; Icagasioglu, A; Basaran, S; Tikiz, C; Kaydok, E; Kaya, T; Karatas, GK; Baygutalp, F; Celebi, G; Yilmaz, F; Önes, K; Akkus, S; Yumusakhuylu, Y; Durlanik, G; Dogu, B; Öncü, J; Sari, A; Özkan, FÜ; Kaysin, MY; Taskiran, ÖÖ; Erol, AM; Eskiyurt, N
    Objective: In this study, it was aimed to evaluate the relationship between vitamin D level and pain severity, localization and duration in patients with non-specific musculoskeletal pain. Materials and Methods: Patients who applied to physical medicine and rehabilitation outpatient clinics due to non-specific muscle pain in 19 centers in Turkey were retrospectively screened. Three thousand four hundred fourpatients were included in the study, whose pain level was determined by visual analog scale (VAS) and the painful region, duration of pain and vitamin D level were reached. D group was found to be D deficient (group 1) when 25 (OH) D level was 20 ng/mL or less and group D 2 (vitamin D deficiency) was higher than 30 ng/mL (group 3). The groups were compared in terms of pain duration, localization and severity. In addition, the correlations of pain localization, severity and duration with vitamin D levels were examined. Results: D vitamin deficiency was detected in 2202 (70.9%) of 3 thousand four hundred and four registered patients, and it was found that vitamin D deficiency in 516 (16.6%) and normal vitamin D in 386 (12.4%). The groups were similar in terms of age, body mass index, income level, duration of complaint, education level, family type and working status (p>0.05). There was no statistically significant difference between groups in terms of VAS, pain localization and duration scores (p>0.05). Conclusion: Our study shows that vitamin D deficiency in patients with nonspecific musculoskeletal pain is not associated with the severity and duration of pain.
  • No Thumbnail Available
    Item
    Demographic and clinical characteristics of inpatient stroke patients in Turkey
    Külcü, DG; Kuran, B; Karahan, AY; Özgirgin, N; Basaran, S; Yaliman, A; Savas, S; Tikiz, C; Aktas, I; Bardak, A; Tuncer, T; Yilmaz, F; Erhan, B; Sirzai, H; Çelik, B; Durlanik, G; Dogu, B; Öncü, J; Hüner, B; Öztürk, G; Eskiyurt, N; Akpinar, FM; Özkan, FU; Paker, N; Bugdayci, DS; Gündüz, B; Satir, Ö; Atalay, NS; Yildiz, N; Altindag, Ö; Demir, SE; Kaya, E; Uçar, D; Sari, A; Karatas, GK; Taskiran, ÖÖ
    Objectives: This study aims to assess the stroke rehabilitation facilities provided by university hospitals (UHs) and training and research hospitals (TRHs) and to evaluate the geographical disparities in stroke rehabilitation. Patients and methods: Between April 2013 and April 2014 a total of 1,529 stroke patients (817 males, 712 females; mean age: 61.7 +/- 14.0 years; range, 12 to 91 years) who were admitted to the physical medicine and rehabilitation clinics in 20 tertiary care centers were retrospectively analyzed. Demographic, regional and clinical characteristics, details of rehabilitation period, functional status, and complications were collected. Results: The median duration of stroke was five (range, 1 to 360) months. The ratio of the patients treated in the TRH in the Marmara region was 77%, but only 25% of the patients were living in the Marmara region. Duration of hospitalization was longer in the TRHs with a median of 28 days compared to those of UHs (median: 22 days) (p<0.0001). More than half of the patients (55%) were rehabilitated in the Marmara region. Time after stroke was the highest in the Southeast region with a median of 12 (range, 1 to 230) months and the lowest in the Aegean region with a median of four (range, 1 to 84) months. Conclusion: This study provides an insight into the situation of stroke rehabilitation settings and characteristics of stroke patients in Turkey. A standard method of patient evaluation and a registry system may provide data about the efficacy of stroke rehabilitation and may help to focus on the problems that hinder a better outcome.
  • No Thumbnail Available
    Item
    Assessment of the Relationship Between Vitamin D Level and Non-specific Musculoskeletal System Pain: A Multicenter Retrospective Study (Stroke Study Group) (vol 23, pg 61, 2017)
    Karahan, AY; Hüner, B; Kuran, B; Sezer, N; Çelik, C; Salbas, E; Ordahan, B; Karaca, G; Yilmaz, H; Gündüz, B; Erhan, B; Bugdayci, DS; Bardak, A; Paker, N; Külcü, DG; Yaliman, A; Atalay, NS; Yildiz, N; Içagasioglu, A; Basaran, S; Tikiz, C; Kaydok, E; Kaya, T; Karatas, GK; Baygutalp, F; Çelebi, G; Yilmaz, F; Önes, K; Akkus, S; Yumusakhuylu, Y; Durlanik, G; Dogu, B; Öncü, J; Sari, A; Özkan, FU; Kaysin, MY; Taskiran, OO; Erol, AM; Eskiyurt, N
  • No Thumbnail Available
    Item
    2017 update of the Turkish League Against Rheumatism (TLAR) evidence-based recommendations for the management of knee osteoarthritis
    Tuncer, T; Cay, FH; Altan, L; Gurer, G; Kacar, C; Ozcakir, S; Atik, S; Ayhan, F; Durmaz, B; Eskiyurt, N; Genc, H; GokceKutsal, Y; Gunaydin, R; Hepguler, S; Hizmetli, S; Kaya, T; Kurtais, Y; Saridogan, M; Sindel, D; Sutbeyaz, S; Sendur, OF; Ugurlu, H; Unlu, Z
    In a Turkish League Against Rheumatism (TLAR) project, evidence-based recommendations for the management of knee osteoarthritis (OA) was developed for the first time in our country in 2012 (TLAR-2012). In accordance with developing medical knowledge and scientific evidence, recommendations were updated. The committee was composed of 22 physical medicine and rehabilitation specialists (4 have rheumatology subspeciality also) and an orthopaedic surgeon. Systematic literature search were applied on Pubmed, Embase, Cochrane and Turkish Medical Index for the dates between January the 1st 2012 and January the 29th of 2015. The articles were assessed for quality and classified according to hierarchy for the level of evidence, and the selected ones sent to committee members electronically. They were asked to develop new recommendations. In the meeting in 2015, the format of the recommendations was decided to be patient-based and considering the grade and the severity of the disease. By the discussion of the each item under the light of new evidences, the final recommendations were developed. Each item was voted electronically on a 10-cm visual analogue scale (VAS) and the strength of recommendation (SoR) was calculated. In the light of evidences, totally 11 titles of recommendations were developed; the first 7 were applicable to each patient in every stages of the disease, remaining were for defined specific clinical situations. The mean SoR value of the recommendations was between 7.44 and 9.93. TLAR-2012 recommendations were updated in a new format. We think that, present recommendations will be beneficial for the physicians who manage, as well as the patients who suffer from the disease.
  • No Thumbnail Available
    Item
    Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
    Aki, S; Eskiyurt, N; Akarirmak, Ü; Tüzün, F; Eryavuz, M; Alper, S; Arpacioglu, O; Atalay, F; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Özerbil, Ö; Savas, G; Sendur, ÖF; Soy, D; Akyüz, G
    The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non-placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 +/- 8.6, with 51.2% in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).
  • No Thumbnail Available
    Item
    Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
    Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardiç, F; Bütün, B; Akyüz, G; Cerrahoglu, L; Sendur, ÖF; Yalçin, P; Öncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gürsoy, S; Cantürk, F; Demir, H; Özdener, F; Öncel, H
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7 +/- 9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered YES to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3 +/- 17.7 points), quality of life (10.4 +/- 20.4 points), overall satisfaction (11.9 +/- 22.7 points), and side effects (3.3 +/- 18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (>= 80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012; 18: 1-7)
  • No Thumbnail Available
    Item
    Evidence-Based Recommendations for the Management of Knee Osteoarthritis: A Consensus Report of the Turkish League Against Rheumatism
    Tuncer, T; Çay, HF; Kaçar, C; Altan, L; Atik, OS; Aydin, AT; Ayhan, FF; Yanik, BÇ; Durmaz, B; Eskiyurt, N; Genç, H; Kutsal, YG; Günaydin, R; Hepgüler, S; Hizmetli, S; Kaya, T; Kurtais, Y; Ölmez, N; Saridogan, M; Sindel, D; Tur, BS; Sütbeyaz, S; Sendur, ÖF; Ugurlu, H; Ünlü, Z
    Objectives: Knee osteoarthritis (OA) is a common disease which causes pain, disability and great socioeconomic burden as a result. Turkish League Against Rheumatism (TLAR) initiated a project to prepare national, evidence-based recommendations for the management of knee osteoarthritis supported by expert-opinion in order to assist the physicians who are interested in knee OA in their daily clinical practice. Materials and methods: The expert committee was composed of 25 academicians, 23 of whom were physical medicine and rehabilitation (PM&R) specialists (three also had rheumatology subspeciality) and two were orthopedic surgeons. At the first meeting, the previous guidelines were discussed, and 2008 Osteoarthritis Research Society International (OARSI) recommendations were decided to be taken as the fundamental template for national recommendations. Databases of the Pubmed, Embase, Cochrane, and Turkish Medical Index were used to search the literature, and this was carried out for the period between 2009-2010 for international publications since studies up to 2009 were present in the 2010 OARSI update. No limit was applied for searching of national publications. The selected relevant publications were graded according to evidence level and quality, and were sent to the members who were then asked to suggest propositions according to their experiences, knowledge, and review of the literature. After amalgamation and editing of new proposals, Delphi rounds were started. After five Delphi rounds, the propositions on which the members were in consensus, were discussed with regard to evidence and the strength of recommendation was determined by measuring on visual analog scale (VAS) for each proposal at the final meeting. Results: Nineteen propositions (one for general principles, nine for non-pharmacologic treatments, seven for pharmacologic treatments, and two for surgical treatments) were accepted as the TLAR Evidence-Based Recommendations for the Management of Knee OA in consensus as a result of Delphi rounds. Conclusion: Evidence-based recommendations for the management of knee OA were developed by TLAR for the first time in our country. The recommendations should be updated regularly according to new evidence and insights. It is expected that physicians who are interested in knee OA will benefit greatly from this report in their daily clinical practice.
  • No Thumbnail Available
    Item
    A CANDIDATE INDENTIFICATION QUESTIONNAIRE FOR PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS SWITCHED FROM TREATMENT WITH A DIALY OR WEEKLY BISHPOSPHONATE TO ONCE-MONTHLY IBANDRONATE-BONCURE: RESULTS OF TURKISH SUB-STUDY
    Eskiyurt, N; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gursoy, S; Canturk, F; Irdesel, J; Demir, H; Ozdener, F; Oncel, H; Serpici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Butun, B; Akyuz, G; Cerrahoglu, L
  • No Thumbnail Available
    Item
    A candidate-identification questionnaire for patients with postmenopausal osteoporosis switched from treatment with a daily or weekly bisphosphonate to once-monthly ibandronate
    Kutsal, YG; Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Korsic, M; Vlak, T; Grlickov, M; Temelkova, SM; Lazarov, M; Pilipovic, N; Popovic, V; Dimic, A; Kovacev, B; Ruci, D; Tafaj, A; Kucukalic-Selimovic, E; Avdic, D; Seleskovic, H; Pejicic, S; Butun, B; Akyuz, G; Cerrahoglu, L; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Senel, K; Gursoy, S; Cantürk, F; Demir, H; Miskic, B; Krpan, D; Skreb, F; Grazio, S; Crncevic-Orlic, Z; Ozdener, F; Oncel, H